Schedule 13G ownership disclosure

Cartesian Therapeutics Inc

Common Stock · CUSIP: 816212302

Event date: 2026-03-09

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Squarepoint Ops LLC

    Shares: 2,209,601.00 · Class: 8.3%

  • Squarepoint Capital LLP

    Shares: 2,209,601.00 · Class: 8.3%

  • Squarepoint Operations Private Limited

    Shares: 2,209,601.00 · Class: 8.3%

  • Squarepoint (DIFC) Ltd

    Shares: 2,209,601.00 · Class: 8.3%

  • Squarepoint Master Fund Limited

    Shares: 2,178,652.00 · Class: 8.2%

  • Squarepoint Core Master Fund Limited

    Shares: 30,949.00 · Class: 0.1%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001642575-26-000003
Form type
SCHEDULE 13G
Filer
Cartesian Therapeutics, Inc.
CIK
CIK 1453687
Filed
Mar 13, 2026
Reporting period
Mar 09, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub